CombinatoRx (CRXX) Reports Phase 2b Trials of Synavive Did Not Demonstrate Statistical Significance
More News related to CRXX
- CombinatoRx Concentrates on Core Strengths
- CombinatoRx Reports Financial Results for the Third Quarter 2008
- CombinatoRx to Present at Upcoming Investor Conferences
- CombinatoRx to Webcast Conference Call Discussing Third Quarter 2008 Financial Results
- CombinatoRx Provides In-Depth Analysis from Phase 2b Knee Osteoarthritis Study of Synavive (CRx-102) with Clinical Investigators
More News related to Corporate News
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
CombinatoRx, Incorporated (NASDAQ: CRXX), today announced preliminary top-line results from COMET-1, the Company's Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive in subjects with symptomatic knee osteoarthritis.
While there was a trend in favor of Synavive, and an observed dose-response relationship, the combination did not demonstrate statistical significance compared to placebo for WOMAC question #1 measuring pain while walking on a flat surface (the primary endpoint), nor when compared to prednisolone alone. Analyses of the full dataset from the study remain ongoing.
CombinatoRx, Incorporated, a biopharmaceutical company, develops synergistic combinations of approved drugs, with a portfolio of product candidates in Phase II clinical development, using its proprietary combination high throughput screening (cHTS) technology.
Related Categories
Corporate NewsStocks Mentioned
-0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
